Literature DB >> 19809933

Effectiveness of low dose of topiramate following rapid titration in multiply handicapped children and difficult-to-treat epilepsy.

G Kluger1, B Schäuble, K Rettig, A Schreiner, H Holthausen.   

Abstract

This prospective, observational, single arm, monocentric study explored efficacy and tolerability outcomes of rapid oral initiation of topimarate in children with difficult to treat epilepsy. The study population consisted of 19 multiply handicapped children (mean age 4.4 years, range 0.6-15.3 years). The observation period was 12 weeks and included 7 visits. The mean initial dose of topiramate was 1.1 mg/kg body weight/d (range: 0.66-2.67 mg/kg/d) following rapid titration. The mean final dose was 3.3 mg/kg/d (range 0.5-6.7 mg/kg/d). An at least 50% reduction of seizure frequency compared to baseline was observed in 9 of 19 patients (47.4%). Six patients (31.6%) had a slight reduction of seizure frequency (<50%) and 4 patients (21.1%) experienced an increase of seizure frequency. A total number of 29 adverse events were documented in 17 of 19 patients. Most frequently captured were fatigue (26.3% of patients), decreased appetite (15.8%) and psychiatric disturbances (15.8%). No serious adverse events were reported. These data might suggest that in certain clinical circumstances rapid dose escalation with topiramate followed by a low maintenance dose might be a good therapeutic option for pediatric patients with difficult to treat epilepsy. (c) Georg Thieme Verlag KG Stuttgart, New York.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19809933     DOI: 10.1055/s-0029-1234103

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  2 in total

Review 1.  Impact of Antiseizure Medications on Appetite and Weight in Children.

Authors:  Ersida Buraniqi; Hicham Dabaja; Elaine C Wirrell
Journal:  Paediatr Drugs       Date:  2022-05-21       Impact factor: 3.022

Review 2.  Topiramate and cognitive impairment: evidence and clinical implications.

Authors:  Marco Mula
Journal:  Ther Adv Drug Saf       Date:  2012-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.